273 related articles for article (PubMed ID: 21502403)
21. Molecular and biologic analysis of histone deacetylase inhibitors with diverse specificities.
Newbold A; Matthews GM; Bots M; Cluse LA; Clarke CJ; Banks KM; Cullinane C; Bolden JE; Christiansen AJ; Dickins RA; Miccolo C; Chiocca S; Kral AM; Ozerova ND; Miller TA; Methot JL; Richon VM; Secrist JP; Minucci S; Johnstone RW
Mol Cancer Ther; 2013 Dec; 12(12):2709-21. PubMed ID: 24092806
[TBL] [Abstract][Full Text] [Related]
22. Histone deacetylase inhibition restores cisplatin sensitivity of Hodgkin's lymphoma cells.
Kewitz S; Bernig T; Staege MS
Leuk Res; 2012 Jun; 36(6):773-8. PubMed ID: 22424710
[TBL] [Abstract][Full Text] [Related]
23. Ricolinostat, a selective HDAC6 inhibitor, shows anti-lymphoma cell activity alone and in combination with bendamustine.
Cosenza M; Civallero M; Marcheselli L; Sacchi S; Pozzi S
Apoptosis; 2017 Jun; 22(6):827-840. PubMed ID: 28315173
[TBL] [Abstract][Full Text] [Related]
24. Coadministration of histone deacetylase inhibitors and perifosine synergistically induces apoptosis in human leukemia cells through Akt and ERK1/2 inactivation and the generation of ceramide and reactive oxygen species.
Rahmani M; Reese E; Dai Y; Bauer C; Payne SG; Dent P; Spiegel S; Grant S
Cancer Res; 2005 Mar; 65(6):2422-32. PubMed ID: 15781658
[TBL] [Abstract][Full Text] [Related]
25. Kinome profiling analysis identified Src pathway as a novel therapeutic target in combination with histone deacetylase inhibitors for cutaneous T-cell lymphoma.
Jimura N; Fujii K; Qiao Z; Tsuchiya R; Yoshimatsu Y; Kondo T; Kanekura T
J Dermatol Sci; 2021 Mar; 101(3):194-201. PubMed ID: 33531202
[TBL] [Abstract][Full Text] [Related]
26. Acute sensitization of colon cancer cells to inflammatory cytokines by prophase arrest.
Kuratnik A; Senapati VE; Verma R; Mellone BG; Vella AT; Giardina C
Biochem Pharmacol; 2012 May; 83(9):1217-28. PubMed ID: 22306067
[TBL] [Abstract][Full Text] [Related]
27. Vorinostat synergizes with EGFR inhibitors in NSCLC cells by increasing ROS via up-regulation of the major mitochondrial porin VDAC1 and modulation of the c-Myc-NRF2-KEAP1 pathway.
Leone A; Roca MS; Ciardiello C; Terranova-Barberio M; Vitagliano C; Ciliberto G; Mancini R; Di Gennaro E; Bruzzese F; Budillon A
Free Radic Biol Med; 2015 Dec; 89():287-99. PubMed ID: 26409771
[TBL] [Abstract][Full Text] [Related]
28. Combining the pan-aurora kinase inhibitor AMG 900 with histone deacetylase inhibitors enhances antitumor activity in prostate cancer.
Paller CJ; Wissing MD; Mendonca J; Sharma A; Kim E; Kim HS; Kortenhorst MS; Gerber S; Rosen M; Shaikh F; Zahurak ML; Rudek MA; Hammers H; Rudin CM; Carducci MA; Kachhap SK
Cancer Med; 2014 Oct; 3(5):1322-35. PubMed ID: 24989836
[TBL] [Abstract][Full Text] [Related]
29. Combined targeting of histone deacetylases and hedgehog signaling enhances cytoxicity in pancreatic cancer.
Chun SG; Zhou W; Yee NS
Cancer Biol Ther; 2009 Jul; 8(14):1328-39. PubMed ID: 19421011
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of autophagy significantly enhances combination therapy with sorafenib and HDAC inhibitors for human hepatoma cells.
Yuan H; Li AJ; Ma SL; Cui LJ; Wu B; Yin L; Wu MC
World J Gastroenterol; 2014 May; 20(17):4953-62. PubMed ID: 24833845
[TBL] [Abstract][Full Text] [Related]
31. Histone deacetylase inhibitor prevents cell growth in Burkitt's lymphoma by regulating PI3K/Akt pathways and leads to upregulation of miR-143, miR-145, and miR-101.
Ferreira AC; Robaina MC; Rezende LM; Severino P; Klumb CE
Ann Hematol; 2014 Jun; 93(6):983-93. PubMed ID: 24577510
[TBL] [Abstract][Full Text] [Related]
32. Mcl-1 and FBW7 control a dominant survival pathway underlying HDAC and Bcl-2 inhibitor synergy in squamous cell carcinoma.
He L; Torres-Lockhart K; Forster N; Ramakrishnan S; Greninger P; Garnett MJ; McDermott U; Rothenberg SM; Benes CH; Ellisen LW
Cancer Discov; 2013 Mar; 3(3):324-37. PubMed ID: 23274910
[TBL] [Abstract][Full Text] [Related]
33. Therapeutic targeting of Polo-like kinase-1 and Aurora kinases in T-cell acute lymphoblastic leukemia.
Spartà AM; Bressanin D; Chiarini F; Lonetti A; Cappellini A; Evangelisti C; Evangelisti C; Melchionda F; Pession A; Bertaina A; Locatelli F; McCubrey JA; Martelli AM
Cell Cycle; 2014; 13(14):2237-47. PubMed ID: 24874015
[TBL] [Abstract][Full Text] [Related]
34. Modulation of thymidilate synthase and p53 expression by HDAC inhibitor vorinostat resulted in synergistic antitumor effect in combination with 5FU or raltitrexed.
Di Gennaro E; Bruzzese F; Pepe S; Leone A; Delrio P; Subbarayan PR; Avallone A; Budillon A
Cancer Biol Ther; 2009 May; 8(9):782-91. PubMed ID: 19270508
[TBL] [Abstract][Full Text] [Related]
35. PLK1 inhibitors synergistically potentiate HDAC inhibitor lethality in imatinib mesylate-sensitive or -resistant BCR/ABL+ leukemia cells in vitro and in vivo.
Dasmahapatra G; Patel H; Nguyen T; Attkisson E; Grant S
Clin Cancer Res; 2013 Jan; 19(2):404-14. PubMed ID: 23204129
[TBL] [Abstract][Full Text] [Related]
36. The role of p21(waf1/cip1) and p27(Kip1) in HDACi-mediated tumor cell death and cell cycle arrest in the Eμ-myc model of B-cell lymphoma.
Newbold A; Salmon JM; Martin BP; Stanley K; Johnstone RW
Oncogene; 2014 Nov; 33(47):5415-23. PubMed ID: 24292681
[TBL] [Abstract][Full Text] [Related]
37. Vorinostat synergizes with ridaforolimus and abrogates the ridaforolimus-induced activation of AKT in synovial sarcoma cells.
Morgan SS; Cranmer LD
BMC Res Notes; 2014 Nov; 7():812. PubMed ID: 25406429
[TBL] [Abstract][Full Text] [Related]
38. Therapeutic potential of a synthetic lethal interaction between the MYC proto-oncogene and inhibition of aurora-B kinase.
Yang D; Liu H; Goga A; Kim S; Yuneva M; Bishop JM
Proc Natl Acad Sci U S A; 2010 Aug; 107(31):13836-41. PubMed ID: 20643922
[TBL] [Abstract][Full Text] [Related]
39. Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma.
Lindemann RK; Newbold A; Whitecross KF; Cluse LA; Frew AJ; Ellis L; Williams S; Wiegmans AP; Dear AE; Scott CL; Pellegrini M; Wei A; Richon VM; Marks PA; Lowe SW; Smyth MJ; Johnstone RW
Proc Natl Acad Sci U S A; 2007 May; 104(19):8071-6. PubMed ID: 17470784
[TBL] [Abstract][Full Text] [Related]
40. Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair.
Lee JH; Choy ML; Ngo L; Foster SS; Marks PA
Proc Natl Acad Sci U S A; 2010 Aug; 107(33):14639-44. PubMed ID: 20679231
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
